Search

Displaying results 5621 - 5630 of 10000 in total
  1. Drug

    RGX-181

    go.drugbank.com/drugs/DB17942
    Experimental

    RGX-181 consists of an adeno-associated virus serotype 9 (AAV9) vector designed to deliver the soluble lysosomal enzyme tripeptidyl peptidase I (TPP1) gene.

  2. Drug

    RP01

    go.drugbank.com/drugs/DB05751
    Experimental

    RP01 is a novel anti-IgE immunotherapy for allergic individuals. … It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response.

  3. Drug

    IC41

    go.drugbank.com/drugs/DB05776
    Investigational

    IC41 is a therapeutic peptide vaccine. It is being devloped by Intercell AG for the treatment of hepatitis C.

  4. Drug

    alpha-Hydroxy glycineamide

    go.drugbank.com/drugs/DB06568
    Experimental

    It also has an effect on viral gp160 envelope protein. [A31692]

  5. Drug

    Gavestinel

    go.drugbank.com/drugs/DB06741
    Experimental

    Highly potent and selective non-competitive antagonist acting at the strychnine-insensitive glycine binding site of the NMDA receptor-channel complex (Kd = 0.8 nM).

    Salts: Gv 150526a
  6. Drug

    ALT-2074

    go.drugbank.com/drugs/DB05631
    Investigational

    An organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated.

  7. Drug

    Pradofloxacin

    go.drugbank.com/drugs/DB11453
    ExperimentalVet approved

    Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal Health GmBH.

  8. Drug

    CX-2009

    go.drugbank.com/drugs/DB16090
    Investigational

    CX-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors).

  9. Drug

    Ralmitaront

    go.drugbank.com/drugs/DB19128
    Investigational

    Ralmitaront is under investigation in clinical trial NCT04512066 (A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or

  10. Drug

    Talampanel

    go.drugbank.com/drugs/DB04982
    Investigational

    Talampanel is a substance that is being studied in the treatment of brain tumors and other brain disorders, such as epilepsy and Parkinson disease. It is a type of AMPA receptor antagonist.